D-Ser(8)-Liraglutide

Name: D-Ser(8)-Liraglutide
Brand: SIAL

GLP-1 Agonist Impurity, analytical standard, Numbering in the name as per API

Synonym(e):

D-Ser(14)-Liraglutide [GLP-1 numbering], H-His-Ala-Glu-Gly-Thr-Phe-Thr-D-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(γ-Glu-palmitoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern

Über diesen Artikel

Empirische Formel (Hill-System):

C₁₇₂H₂₆₅N₄₃O₅₁

Molekulargewicht:

3751.20

UNSPSC Code:

41116107

eCl@ss:

25140904

Technischer Dienst

Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.

Unterstützung erhalten

Eigenschaften

grade

analytical standard

Quality Segment

100

API family

liraglutide, liraglutide, liraglutide, liraglutide

form

powder, solid

technique(s)

HPLC: suitable, LC/MS: suitable, liquid chromatography (LC): suitable, mass spectrometry (MS): suitable

color

white to off-white

format

neat

storage temp.

−20°C

SMILES string

OC[C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](N)CC1=CNC=N1)=O)C)=O)CCC(O)=O)=O)=O)[C@@H](C)O)=O)CC2=CC=CC=C2)=O)[C@@H](C)O)=O)CO)=O)CC(O)=O)=O)C(C)C)=O)CO)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCC(O)=O)C(N[C@@H](CC3=CC=CC=C3)C(N[C@H](C(N[C@@H](C)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CCCNC(N)=N)C(NCC(O)=O)=O)=O)=O)=O)C(C)C)=O)CC(C)C)=O)CC4=CNC5=CC=CC=C45)=O)=O)[C@H](CC)C)=O)=O)=O)CCCCNC(CC[C@H](NC(CCCCCCCCCCCCCCC)=O)C(O)=O)=O)=O)C)=O)C)=O)CCC(N)=O)=O)=O)CCC(O)=O)=O)CC(C)C)=O)CC6=CC=C(C=C6)O)=O

Beschreibung

General description

The analytical standard of D-Ser(8)-Liraglutide is a stereoisomeric impurity of Liraglutide in which the L-Serine residue at position 8, API numbering (and position 14 in GLP-1 numbering) is replaced by its D-enantiomer (D-Ser). This single chiral inversion, two residues from the N-terminus, can arise during solid-phase peptide synthesis (SPPS) through incomplete chiral control or racemisation under acidic/basic coupling conditions. The compound retains the full 31-residue backbone of Liraglutide and carries the characteristic palmitoyl–γGlu–Lys26 fatty acid conjugate responsible for albumin binding and extended half-life. However, the D-amino acid substitution is expected to locally distort the α-helical secondary structure, potentially altering GLP-1 receptor binding affinity and metabolic stability.

Application

Used as an analytical standard for the identification and semi-quantification of the D-Ser-8 stereoisomeric impurity in Liraglutide API by reversed-phase HPLC, chiral chromatography, and LC-MS/MS methods.